News — Pacific 8 Ventures
Fauna Bio raises $9 Million to expand the comparative genomics platform for novel target discovery. This round is led by LifeForce Capital with participation from previous investors including Pacific 8 Ventures, True Ventures, and more.
Huge congratulations to Oguzhan, David, and the exceptional BillionToOne team on securing $130 million in an oversubscribed Series D funding round. This funding will further revolutionize the prenatal screening and oncology diagnostics landscape. Read More —> Read more → June 21, 2024 Mammoth and Regeneron will collaborate on in vivo CRISPR-based gene editing therapies in a deal worth $100 million upfront plus $370 million in milestones per target. Read More —> Read more → April 25, 2024 Fauna Bio improving human health by leveraging animal genomics, today announced a multi-year…
saved by
related reading
- Mission BioCapital collects $275m for fifth fundventurecapitaljournal.com
- Gap Mapgap-map.org
- List of Biotechnology Companies to Watch – AI Expanded Versionsubstack.com
- An ancient RNA-guided system could simplify delivery of gene editing therapiesbroadinstitute.org
- The Frontier in 2025renaissancephilanthropy.org
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- The 23andMe Deal - Cremieux Recueilcremieux.xyz
- Nature Biotechnology’s academic spinouts of 2019nature.com
- AI-Powered Drug Discovery Platform | Deep Origindeeporigin.com
- The Practical Guide to Superbabies — LessWronglesswrong.com
- Extreme Biologycenturyofbio.substack.com
- Hub-and-Spoke Biotechs: BridgeBio - by Elliot Hershbergcenturyofbio.com